Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
Share:
CARLSBAD, Calif. - Life Technologies Corporation (NASDAQ: LIFE) today announced that the new Center for Personalized Medicine (CPM) at Roswell Park Cancer Institute (RPCI) has purchased four Ion Proton™ sequencers and two Ion Personal Genome Machine™ (PGM™) sequencers.
Founded in 1898, Roswell Park Cancer Institute was one of the first cancer centers in the country to be named a National Cancer Institute-designated comprehensive cancer center and is a member of the prestigious National Comprehensive Cancer Network.
"A key part of our mission at the Center involves research into new therapies, new diagnostic tools and better ways of predicting patient outcomes," said Carl Morrison, MD, DVM, Executive Director of the Center for Personalized Medicine. "The sequencers will be central to this work, quickly generating vast amounts of genomic data that will help us to understand the mechanisms of how cancer develops and spreads."
"The combination of the Ion Proton™ sequencer and the Ion PGM™ sequencer will give the researchers from Roswell Park Cancer Institute a simple workflow from discovery to validation," said Life Technologies President and Chief Operating Officer Mark Stevenson. "Over 1,000 organizations have adopted Ion Torrent technology in the past two years, giving our company more than 60 percent of the desktop sequencer market and reflecting the huge demand for the speed, simplicity and affordability of Ion Torrent technology."
All products referenced are for research use only and not for use in diagnostic procedures.
About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company with customers in more than 160 countries using its innovative solutions to solve some of today's most difficult scientific challenges. Quality and innovation are accessible to every lab with its reliable and easy-to-use solutions spanning the biological spectrum, with more than 50,000 products for agricultural biotechnology, translational research, molecular medicine and diagnostics, stem cell-based therapies, forensics, food safety and animal health. Its systems, reagents and consumables represent some of the most cited brands in scientific research including: Ion Torrent™, Applied Biosystems®, Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®. Life Technologies employs approximately 10,400 people and upholds its ongoing commitment to innovation with more than 4,000 patents and exclusive licenses. LIFE had sales of $3.8 billion in 2012. Visit us at our website: http://www.lifetechnologies.com.
Life Technologies Contact
Wes Conard
650-243-6019
wes.conard@lifetech.com
SOURCEÂ
Life Technologies Corporation
Web Site: http://www.lifetechnologies.com
